Regulation and specificity of deubiquitylating enzyme complex

去泛素化酶复合物的调节和特异性

基本信息

  • 批准号:
    8618909
  • 负责人:
  • 金额:
    $ 25.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-01 至 2017-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Abnormal regulation of human deubiquitylating enzymes (DUBs) has been implicated in the pathogenesis of a number of human diseases including cancer, neurodegenerative disorders and viral infection. Ubiquitin-specific proteases (USPs) constitute the largest family among the five known DUB families. Human USPs are emerging as promising targets for pharmacological intervention. However, the lack of understanding of the specificity and regulation of USPs has hindered the progress in developing novel therapeutics. Remarkably, a recent global proteomic analysis of human DUBs revealed that over thirty human USPs are associated specifically with WD40-repeat proteins. Given its widespread occurrence, the interaction between WD40- repeat proteins and USPs likely represents a fundamentally important way of regulating USP activity. This application focuses on a prototypical USP WD40-repeat protein complex, human USP1/UAF1, and its close homologs. The overarching goal of this application is to gain an in-depth understanding of the specificity and regulation of human USPs and the USP WD40-repeat protein complexes. There are three specific aims: 1) Determine the energetics of the bipartite USP-Ub interaction in USP1 and USP2 (a structural homolog of USP1). Assess the contribution of the bipartite interaction to ubiquitin recognition and catalysis by double mutation analysis; 2) Probe the specificity of USP1/UAF1 using a physiological substrate and its close mimics. A new AlphaScreen-based assay will be developed to improve both the throughput and sensitivity of the deubiquitylation assay; 3) Determine the molecular mechanism by which UAF1 upregulates the activity of USP1 and the closely related human USP46. We will characterize the USP1/UAF1 and USP46/UAF1 complexes and map the interaction sites between UAF1 and the two USPs. The molecular basis for the stimulation of the USP enzymatic activity by UAF1 will be interrogated by enzymological approaches. Taken together, these studies have the potential to uncover important insights into the specificity and regulation of the prevalent USP WD40-repeat protein complexes. Further, our study will suggest new directions for pharmacologic intervention of this important class of human USPs.
描述(由申请人提供):人去泛素化酶(DUBs)的异常调节与许多人类疾病的发病机制有关,包括癌症、神经退行性疾病和病毒感染。泛素特异性蛋白酶(USPs)是五个已知DUB家族中最大的家族。人类USPs正在成为药理学干预的有希望的目标。然而,缺乏对USPs的特异性和调控的理解阻碍了开发新疗法的进展。值得注意的是,最近对人类dub的全球蛋白质组学分析显示,超过30个人类USPs与wd40重复蛋白特异性相关。鉴于其广泛存在,WD40-重复蛋白与USP之间的相互作用可能是调节USP活性的重要途径。本应用程序的重点是一个原型的USP wd40重复蛋白复合物,人类USP1/UAF1,及其密切的同源物。本申请的总体目标是深入了解人类USP和USP WD40-repeat蛋白复合物的特异性和调控。有三个具体目的:1)确定USP1和USP2 (USP1的结构同源物)中USP-Ub相互作用的能量学。通过双突变分析评估两部分相互作用对泛素识别和催化的贡献;2)利用生理底物及其相近的模拟物探测USP1/UAF1的特异性。将开发一种新的基于alphascreen的检测方法,以提高去泛素化检测的通量和灵敏度;3)确定UAF1上调USP1及与之密切相关的人类USP46活性的分子机制。我们将描述USP1/UAF1和USP46/UAF1复合物,并绘制UAF1与两个USPs之间的相互作用位点。UAF1刺激USP酶活性的分子基础将通过酶学方法进行探讨。综上所述,这些研究有可能揭示普遍的USP WD40-repeat蛋白复合物的特异性和调控的重要见解。此外,我们的研究将为这类重要的人类USPs的药物干预提供新的方向。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhihao Zhuang其他文献

Zhihao Zhuang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhihao Zhuang', 18)}}的其他基金

Investigating autophagic degradation of tau mediated by polyubiquitination
研究多泛素化介导的 tau 自噬降解
  • 批准号:
    10432378
  • 财政年份:
    2022
  • 资助金额:
    $ 25.27万
  • 项目类别:
Developing a cell-based high throughput screening for USP15 deubiquitinase inhibitor discovery
开发基于细胞的高通量筛选以发现 USP15 去泛素酶抑制剂
  • 批准号:
    10287750
  • 财政年份:
    2021
  • 资助金额:
    $ 25.27万
  • 项目类别:
Decoding the non-canonical polyubiquitin chains using chemical approaches
使用化学方法解码非规范多聚泛素链
  • 批准号:
    10364631
  • 财政年份:
    2019
  • 资助金额:
    $ 25.27万
  • 项目类别:
NIH ADMINISTRATIVE SUPPLEMENT AUTOMATED PEPTIDE SYNTHESIZER ZHUANG
NIH 行政补充自动肽合成仪庄
  • 批准号:
    10387411
  • 财政年份:
    2019
  • 资助金额:
    $ 25.27万
  • 项目类别:
Decoding the non-canonical polyubiquitin chains using chemical approaches
使用化学方法解码非规范多聚泛素链
  • 批准号:
    9902465
  • 财政年份:
    2019
  • 资助金额:
    $ 25.27万
  • 项目类别:
Developing ubiquitin chain- and target-specific deubiquitinase probes
开发泛素链和靶标特异性去泛素酶探针
  • 批准号:
    8852722
  • 财政年份:
    2014
  • 资助金额:
    $ 25.27万
  • 项目类别:
Developing ubiquitin chain- and target-specific deubiquitinase probes
开发泛素链和靶标特异性去泛素酶探针
  • 批准号:
    8772352
  • 财政年份:
    2014
  • 资助金额:
    $ 25.27万
  • 项目类别:
Regulation and specificity of deubiquitylating enzyme complex
去泛素化酶复合物的调节和特异性
  • 批准号:
    8297146
  • 财政年份:
    2012
  • 资助金额:
    $ 25.27万
  • 项目类别:
Regulation and specificity of deubiquitylating enzyme complex
去泛素化酶复合物的调节和特异性
  • 批准号:
    8464161
  • 财政年份:
    2012
  • 资助金额:
    $ 25.27万
  • 项目类别:
Regulation and specificity of deubiquitylating enzyme complex
去泛素化酶复合物的调节和特异性
  • 批准号:
    9014551
  • 财政年份:
    2012
  • 资助金额:
    $ 25.27万
  • 项目类别:

相似海外基金

How exercise improves ataxia in SCA6
运动如何改善 SCA6 的共济失调
  • 批准号:
    479005
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
    Operating Grants
Role of POU4F1 in a Novel Form of Ataxia
POU4F1 在新型共济失调中的作用
  • 批准号:
    10741382
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
Exploratoin of Nrf2 activators that potentiate chaperone-mediated autophagy and are useful for the treatment of spinocrebellar ataxia
探索增强伴侣介导的自噬并可用于治疗脊髓小脑共济失调的 Nrf2 激活剂
  • 批准号:
    23K06161
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Defining the role of Tox3 in congenital cerebellar hypoplasia and ataxia
定义 Tox3 在先天性小脑发育不全和共济失调中的作用
  • 批准号:
    10799992
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
Genome-wide dysregulation of R-loops in Ataxia Telangiectasia neurological pathogenesis
共济失调毛细血管扩张症神经发病机制中 R 环的全基因组失调
  • 批准号:
    10607414
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
Identifying the molecular mechanisms of GEMIN5 mutations in a novel cerebellar ataxia syndrome
鉴定新型小脑共济失调综合征中 GEMIN5 突变的分子机制
  • 批准号:
    10753403
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
Project 2: Therapeutic Gene Editing for Friedreich's Ataxia
项目 2:弗里德赖希共济失调的治疗性基因编辑
  • 批准号:
    10668768
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
Molecular Pathogenesis of spinocerebellar ataxia type 12
12 型脊髓小脑共济失调的分子发病机制
  • 批准号:
    10579736
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
The Impact of Vitamin D on mTOR Signaling, Seizures, and Motor Behavior in a Mouse Model of Hyperactive mTOR Induced Epilepsy and Ataxia
维生素 D 对 mTOR 过度活跃诱发癫痫和共济失调小鼠模型中 mTOR 信号传导、癫痫发作和运动行为的影响
  • 批准号:
    10754319
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10740682
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了